Privacy preference
MEDtalks would like to keep you informed about the content that is most relevant to you. Click
here
for more information.
Yes
No
Back
ESMO 2019 First-line nivolumab and low-dose ipilimumab for advanced NSCLC
Chat with us
, powered by
LiveChat